IncyteRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Period | Jakafi net sales ($M) | Reported YoY | Paid demand YoY |
|---|---|---|---|
| Q2 2026 | 817 | 7% | 9% |
| Asset | Printed status | Setting |
|---|---|---|
| Jakafi XR | FDA approved May 2026; launch in Q2. XR sales guided about $40 to $50 million for 2026, inside Jakafi guidance | Once-daily ruxolitinib for MF, PV, and GVHD |
| Opzelura moderate AD (EU) | Positive CHMP opinion June 2026; EC decision expected Q3 2026 | Would be the first topical JAK inhibitor for moderate AD in Europe |
| Latarcibart | Acquired; Phase 3 in von Willebrand disease | Hematology franchise expansion |
| Monjuvi newly diagnosed DLBCL | Global submissions accepted in Q2 2026; potential U.S. approval and launch Q1 2027 | Moves tafasitamab earlier than r/r DLBCL |
| Minjuvi Japan r/r DLBCL | MHLW approval June 2026 with lenalidomide | Second Japan approval for Minjuvi |
| Period | Reported Opzelura ($M) | CMS settlement ($M) | Underlying ($M) |
|---|---|---|---|
| Q2 2026 | 450 | 246 | 204 |